Astrazeneca acquires biotech firm for up to USD 1.3bn

Pharmaceutical giant Astrazeneca is acquiring Teneotwo to get its hands on TNB-486, a potential lymph node cancer candidate.
by marketwire, translated by catherine brett

Astrazeneca has entered an agreement to acquire biotech firm Teneotwo for up to USD 1.3bn, Bloomberg News reports.

The British-Swedish firm is paying USD 100m upfront, while the rest will be in the form of milestone payments connected to development and commercial targets.

The aim of the acquisition is for Astrazeneca to get its hands on an experimental lymph node cancer treatment. The candidate, called TNB-486, is in the early stages of clinical testing, Astrazeneca reports.

Astrazeneca’s share price increased by 3% on Tuesday.

Overview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine market

Moderna on booster race: May the best data win

Genmab to submit cancer candidate epcoritamab to the FDA before year-end

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading